MSN REBOPAG 75 MG 10'S

About

MSN Rebopag 75 mg likely refers to Eltrombopag, a thrombopoietin receptor agonist (TPO-RA). Eltrombopag stimulates the proliferation and differentiation of megakaryocytes from bone marrow stem cells, leading to an increase in platelet production. It achieves this by interacting with the thrombopoietin receptor, a cytokine receptor that plays a crucial role in regulating megakaryopoiesis and platelet production.

This medication is primarily used to treat thrombocytopenia (low platelet count) in various conditions, including chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA), and thrombocytopenia associated with chronic hepatitis C virus (HCV) infection. By increasing platelet counts, eltrombopag helps to reduce the risk of bleeding episodes and allows patients to undergo necessary medical procedures. Regular monitoring of liver function and platelet counts is essential during treatment.

Uses

• Treatment of chronic immune thrombocytopenia (ITP) in adults and pediatric patients.
• Management of severe aplastic anemia (SAA) in adults.
• Treatment of thrombocytopenia in patients with chronic Hepatitis C virus (HCV) infection.
• Used to increase platelet counts to reduce the risk of bleeding.

Directions For Use

Take orally once daily on an empty stomach, at least 1 hour before or 2 hours after meals or other medications containing polyvalent cations (e.g., antacids, dairy products). Swallow the tablet whole.

Benefits

• Effectively increases platelet counts in various thrombocytopenic conditions.
• Reduces the risk of bleeding episodes.
• Allows patients to undergo necessary medical procedures.
• Oral administration offers convenience for patients.
• Can improve quality of life for patients with chronic ITP or SAA.
• Offers a non-immunosuppressive approach to platelet elevation.

Side Effects

• Nausea
• Diarrhea
• Upper respiratory tract infection
• Vomiting
• Abdominal pain
• Fatigue
• Fever
• Cough
• Elevated liver transaminases
• Arthralgia
• Myalgia
• Thromboembolic events (e.g., DVT, PE)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption, as it may exacerbate liver issues, which is a concern with eltrombopag.
• Pregnancy - Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies show reproductive toxicity. Effective contraception is advised for women of childbearing potential.
• Breastfeeding - It is unknown if eltrombopag is excreted in human milk. A decision should be made whether to discontinue breastfeeding or the drug, considering the importance of the drug to the mother.
• Liver - Use with caution in patients with hepatic impairment. Liver function tests should be monitored closely, and dose adjustments may be necessary. Risk of hepatotoxicity.
• Kidney - No specific dose adjustment is required for renal impairment. However, monitor for any changes in renal function.
• Lung - Monitor for signs of thromboembolic events, including pulmonary embolism, especially in patients with risk factors.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.